About AccurKardia
AccurKardia is a company based in New York (United States) founded in 2019 by Tony M Kuttiachen, Juan C Jimenez, Mohamed Sadeq Ali, John Fox, and Naveen Srinivas. AccurKardia has raised $6.81 million across 2 funding rounds from investors including Banco Popular. AccurKardia offers products and services including AccurECG, AK-AVS, and AK+ Guard. AccurKardia operates in a competitive market with competitors including Endotronix, Edwards Lifesciences, CoachCare, BioIntelliSense and Element Science, among others.
- Headquarter New York, United States
- Founders Tony M Kuttiachen, Juan C Jimenez, Mohamed Sadeq Ali, John Fox, Naveen Srinivas
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Accurkardia, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.81 M (USD)
in 2 rounds
-
Latest Funding Round
$4.11 M (USD), Series A
Jun 30, 2023
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AccurKardia
AccurKardia offers a comprehensive portfolio of products and services, including AccurECG, AK-AVS, and AK+ Guard.
Automates ECG analysis for streamlined diagnostics in healthcare settings.
Supports detection of conditions through ECG for investigational use only.
Aids in managing health conditions via ECG signals under development.
People of AccurKardia
Unlock access to complete
Unlock access to complete
Funding Insights of AccurKardia
AccurKardia has successfully raised a total of $6.81M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $4.11 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AccurKardia
AccurKardia has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Banco Popular.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Commercial banking services are offered to individuals and businesses.
|
Locked | Locked | Locked |
Investor details for AccurKardia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AccurKardia
Investment portfolio details for AccurKardia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AccurKardia
Detailed financials for AccurKardia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Accurkardia Comparisons
Peer comparison for AccurKardia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AccurKardia
AccurKardia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Endotronix, Edwards Lifesciences, CoachCare, BioIntelliSense and Element Science, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring.
|
|
| Locked | Locked | Locked |
Medical devices for structural heart disease are developed and provided.
|
|
| Locked | Locked | Locked |
Remote monitoring platform for tracking patient activity
|
|
| Locked | Locked | Locked |
Vital signs are monitored via a single-use patch and platform.
|
|
| Locked | Locked | Locked |
Wearable patch defibrillators are developed for sudden cardiac arrest treatment.
|
|
| Locked | Locked | Locked |
Contactless patient monitoring is provided for mental health facilities.
|
Detailed competitors of AccurKardia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Accurkardia
Complete news archive for AccurKardia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AccurKardia
AccurKardia was founded in 2019 and raised its 1st funding round 4 years after it was founded.
AccurKardia is headquartered in New York, United States. It is registered at New York, New York, United States.
Juan C Jimenez is the current CEO of AccurKardia. They have also founded this company.
AccurKardia is a funded company, having raised a total of $6.81M across 2 funding rounds to date.
AccurKardia was established in 2019 in New York, United States, as a medical AI software firm. Cloud-based solutions are offered for automated ECG interpretation at clinical grade. Real-time cardiac monitoring is facilitated in hospital settings via device-agnostic tools and API integration. Operations focus on enhancing cardiac care through connected systems in the healthcare sector.
AccurKardia's top competitors include Endotronix, Oxehealth and BioIntelliSense.
AccurKardia offers AccurECG, AK-AVS, and AK+ Guard.
AccurKardia has 1 investor. Key investors include Banco Popular.